摘要
目的:探讨神经生长因子对重型颅脑损伤患者血清神经元特异性烯醇化酶(NSE)和髓鞘碱性蛋白(MBP)的影响。方法:80例重型颅脑损伤患者随机分为两组各40例。对照组患者入院后予以降颅内压、抗感染、营养神经和预防并发症等对症治疗,有手术指征者及时手术治疗。观察组患者在此基础上予以鼠神经生长因子18μg,im,qd,疗程2周。结果:治疗2周后,两组患者血浆NSE和MBP水平均较前明显下降(P<0.05或0.01),观察组下降幅度较对照组更明显(P<0.05),且观察组患者GCS评分改善幅度明显优于对照组(P<0.05)。两组患者治疗过程中均未见明显药物不良反应。治疗后6个月随访,观察组患者GCS评分改善幅度亦明显优于对照组(P<0.05)。结论:神经生长因子治疗重型颅脑损伤的近期和远期疗效确切,安全性较好,能明显提高患者的GCS评分,促进患者意识的恢复,作用机制与降低血浆NSE和MBP水平有关。
To explore the effect of NGF on plasma levels of neuronspecific enolase（NSE） and myelin basic protein （MBP） in the patients with severe traumatic brain injury.Method：Totally 80 patients with severe traumatic brain injury were divided into the observation group and the control group.All the patients were received the symptomatic treatment including intracranial pressure reduction,anti-infection,nerve nutrition and complication prevention.The patients with indication of surgery were undertaken surgery in time.The patients in the observation group were additionally received intramuscular injection of 18μg mouse NGF,once a day, for 2 weeks.Result：After the 2-week treatment,the plasma levels of NSE and MBP in the two groups were reduced significantly compared with those before the treatment（P 0.05 or P 0.01 ）,and the decrease in the observation group was more notable than that in the control group（P 0.05）.The improvement of GCS score in the observation group was better as well（P 0.05 ）.No significant adverse reactions were shown in the two groups.The follow-up after 6-month treatment suggested the improvement of GCS score in the observation group was still better than that in the control group（P 0.05）.Conclusion：Treating patients with severe traumatic brain injury with NGF shows promising short- and long-term curative effect with high safety,and can raise GCS score and promote the consciousness recovery by reducing the levels of NSE and MBP.
出处
《中国药师》
CAS
2013年第7期1046-1047,共2页
China Pharmacist
